Skip to main content
AVTR
NYSE Life Sciences

Avantor's Q1 Adjusted EPS of $0.17 and Sales Beat Analyst Estimates

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$7.91
Mkt Cap
$5.314B
52W Low
$7.265
52W High
$15.93
Market data snapshot near publication time

summarizeSummary

Avantor reported Q1 adjusted EPS of $00.17, surpassing the IBES estimate of $00.16. The company also exceeded sales expectations, posting $1,581.4 million against an estimated $1,543 million. This positive earnings report provides a fresh financial update following the company's 2025 net loss and recent executive transition. The beat on both top and bottom lines is a positive signal for investors, indicating better-than-expected operational performance. Traders will now watch for any updated guidance or commentary on future performance.

At the time of this announcement, AVTR was trading at $7.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $7.27 to $15.93. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed AVTR - Latest Insights

AVTR
Apr 29, 2026, 9:02 AM EDT
Filing Type: 10-Q
Importance Score:
8
AVTR
Apr 29, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
7
AVTR
Apr 29, 2026, 6:05 AM EDT
Source: Reuters
Importance Score:
7
AVTR
Apr 23, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
AVTR
Apr 01, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
7
AVTR
Mar 27, 2026, 7:40 AM EDT
Filing Type: DEF 14A
Importance Score:
7
AVTR
Feb 12, 2026, 5:24 PM EST
Filing Type: 4
Importance Score:
7
AVTR
Feb 11, 2026, 7:40 AM EST
Filing Type: 8-K
Importance Score:
8
AVTR
Feb 11, 2026, 7:34 AM EST
Filing Type: 10-K
Importance Score:
9